Never Run Out Of Buyers To Sell To.

4D Path has created a groundbreaking platform, the patented Q-Plasia OncoReader (QPOR™), designed to directly compute cell cycle deregulation and tumor microenvironment dynamics. By accurately predicting a patient’s response to therapy from routine biopsy images, QPOR™ enables precision treatment selection in ways not previously possible. This unprecedented view into tumor dynamics creates new pathways from clinical use to commercial application—bringing more effective, personalized therapies to patients. 4D Path is focused on a bold vision where every person impacted by cancer is diagnosed…
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.